Hepion Pharmaceuticals (HEPA) Competitors $0.07 +0.00 (+0.45%) As of 09/4/2025 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA vs. QLGN, PRFX, SLRX, LIPO, ARDS, WINT, VRAX, CANF, PTIX, and GLMDShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Qualigen Therapeutics (QLGN), PainReform (PRFX), Salarius Pharmaceuticals (SLRX), Lipella Pharmaceuticals (LIPO), Aridis Pharmaceuticals (ARDS), Windtree Therapeutics (WINT), Virax Biolabs Group (VRAX), Can-Fite BioPharma (CANF), Atrinsic (PTIX), and Galmed Pharmaceuticals (GLMD). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Its Competitors Qualigen Therapeutics PainReform Salarius Pharmaceuticals Lipella Pharmaceuticals Aridis Pharmaceuticals Windtree Therapeutics Virax Biolabs Group Can-Fite BioPharma Atrinsic Galmed Pharmaceuticals Hepion Pharmaceuticals (NASDAQ:HEPA) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends. Which has more volatility and risk, HEPA or QLGN? Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. Do institutionals & insiders have more ownership in HEPA or QLGN? 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is HEPA or QLGN more profitable? Qualigen Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Hepion PharmaceuticalsN/A -812.56% -207.31% Qualigen Therapeutics N/A N/A -202.16% Which has preferable earnings and valuation, HEPA or QLGN? Qualigen Therapeutics has higher revenue and earnings than Hepion Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00Qualigen Therapeutics$4.98M0.57-$6.26MN/AN/A Does the media favor HEPA or QLGN? In the previous week, Qualigen Therapeutics had 1 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 1 mentions for Hepion Pharmaceuticals. Qualigen Therapeutics' average media sentiment score of 0.50 beat Hepion Pharmaceuticals' score of -1.00 indicating that Qualigen Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Hepion Pharmaceuticals Negative Qualigen Therapeutics Positive SummaryQualigen Therapeutics beats Hepion Pharmaceuticals on 7 of the 9 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$758K$822.15M$5.76B$9.85BDividend YieldN/A4.84%6.67%4.51%P/E Ratio-0.021.0975.7526.43Price / SalesN/A26.59547.78119.09Price / CashN/A19.5637.0558.92Price / Book0.056.6411.156.06Net Income-$48.93M-$4.78M$3.29B$266.28M7 Day PerformanceN/A1.53%0.20%-0.32%1 Month PerformanceN/A12.43%6.30%3.44%1 Year PerformanceN/A29.37%54.81%23.11% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals0.3152 of 5 stars$0.07+0.5%N/A-99.8%$758KN/A-0.0220Negative NewsShort Interest ↑QLGNQualigen TherapeuticsN/A$1.77-1.1%N/A-81.8%$3.01M$4.98M0.0050News CoveragePositive NewsShort Interest ↓PRFXPainReform0.8824 of 5 stars$1.43-1.4%N/A+88.9%$2.87MN/A-0.014Positive NewsGap DownSLRXSalarius Pharmaceuticals1.0458 of 5 stars$5.40-6.2%N/A-79.1%$2.76MN/A-0.1220Short Interest ↓Gap DownLIPOLipella Pharmaceuticals0.9255 of 5 stars$0.590.0%N/A-82.3%$2.73M$536.36K-0.144Short Interest ↑ARDSAridis PharmaceuticalsN/A$0.05+49,900.0%N/AN/A$2.67MN/A0.0030Gap UpWINTWindtree Therapeutics3.1127 of 5 stars$0.09-5.4%$350.00+388,788.9%-100.0%$2.64MN/A0.0030Short Interest ↓Gap DownVRAXVirax Biolabs Group2.4533 of 5 stars$0.59-2.3%$3.00+406.8%-84.7%$2.57M$10K0.005Short Interest ↑Gap DownCANFCan-Fite BioPharma3.0562 of 5 stars$0.66+4.2%$14.00+2,027.7%-72.2%$2.33M$674K-0.378Analyst ForecastShort Interest ↓PTIXAtrinsic0.305 of 5 stars$3.600.0%N/A-63.2%$2.12MN/A-0.272Positive NewsShort Interest ↑GLMDGalmed Pharmaceuticals1.063 of 5 stars$1.27flatN/A-54.4%$2.10MN/A-0.0820Short Interest ↑ Related Companies and Tools Related Companies QLGN Alternatives PRFX Alternatives SLRX Alternatives LIPO Alternatives ARDS Alternatives WINT Alternatives VRAX Alternatives CANF Alternatives PTIX Alternatives GLMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HEPA) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEPA Stock Alerts